Dale L. Boger

Dale L. Boger

Auto-generated profile, based on publicly available information

Dale L. Boger

Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HIHayato Ishikawa
Hayato Ishikawa
DCDavid A. Colby
David A. Colby
SSShigeki Seto
Shigeki Seto
PVPorino Va
Porino Va
ATAnnie Tam
Annie Tam
DBDale L. Boger
Dale L. Boger

3 August 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TBTimothy J. Barker
Timothy J. Barker
DBDale L. Boger
Dale L. Boger

28 February 2012 in Organic Letters
Verified
Journal Article
Closed access
ELErick K. Leggans
Erick K. Leggans
TBTimothy J. Barker
Timothy J. Barker
KDKatharine K. Duncan
Katharine K. Duncan
DBDale L. Boger
Dale L. Boger

1 July 1996 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
DBDale L. Boger
Dale L. Boger
DJDouglas S. Johnson
Douglas S. Johnson

9 May 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DBDale L. Boger
Dale L. Boger
HSHaruhiko Sato
Haruhiko Sato
ALAaron E. Lerner
Aaron E. Lerner
MHMichael P. Hedrick
Michael P. Hedrick
RFRobert A. Fecik
Robert A. Fecik
BCBenjamin F. Cravatt
Benjamin F. Cravatt
The development of exceptionally potent inhibitors of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid), and anandamide (an endogenous ligand for cannabinoid receptors) is detailed. The inhibitors may serve as useful tools to clarify the role of endogenous oleamide and anandamide and may prove to be useful therapeutic agents for the treatment of sleep disorders or pain. The combination of several features—an optimal C12–C8 chain length, π-unsaturation introduction at the corresponding arachidonoyl Δ8,9/Δ11,12and oleoyl Δ9,10location, and an α-keto N4 oxazolopyridine with incorporation of a second weakly basic nitrogen provided FAAH inhibitors withKis that drop below 200 pM and are 102–103times more potent than the corresponding trifluoromethyl ketones.

23 October 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DBDale L. Boger
Dale L. Boger
HMHiroshi Miyauchi
Hiroshi Miyauchi
WDWu Du
Wu Du
CHChristophe Hardouin
Christophe Hardouin
RFRobert A. Fecik
Robert A. Fecik
BCBenjamin F. Cravatt
Benjamin F. Cravatt